Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2024

Dec 9, 2024

34238_dirs_2024-12-09_8a41ea21-fe39-46b5-ac9a-db347c687fb8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2024-12-05

Reporting Person: James Andrea S. (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-12-05 Common Stock, no par value P 20000 $2.29 Acquired 53670 Direct